Background: RET kinase inhibitors have significant activity in patients with medullary thyroid carcinoma (MTC). Patients and methods: We retrospectively reviewed the electronic medical record for patterns of calcitonin, carcinoembryonic antigen (CEA) and tumor measurement responses in consecutive patients with MTC who received treatment with a RET inhibitor for at least 6 months.
introduction
Medullary thyroid carcinoma (MTC) is a rare malignancy, often associated with mutations in the RET proto-oncogene [1] . An important feature of an MTC tumor is its ability to express and synthesize calcitonin, which is considered an important tumor marker for this disease [2] . In addition to calcitonin, MTCs are also able to produce other serum markers, including carcinoembryonic antigen (CEA). CEA is commonly expressed in colorectal, pancreatic and salivary tumors, as well as many other cancers, and is not therefore a specific biomarker for MTC [3] .
Several multikinase inhibitors that target RET are being tested in the clinical setting, and vandetanib and cabozantinib have been approved [4] . When assessing the effectiveness of RET inhibitors in MTC, calcitonin and CEA levels are routinely monitored in addition to tumor measurements. We have, however, observed that calcitonin and CEA fluctuations may be transient. After a rapid decline in calcitonin and/or CEA, with the initiation of treatment, short-term fluctuations are often observed that do not correspond to long-term changes in tumor size, or the long-term trend in tumor markers themselves. Furthermore, tumor size itself may follow a pattern of initial decline and then oscillation around a plateau. These observations reported herein have important implications for the conduct of clinical trials, which often mandate removing patients from study after 'progression' from nadir size, even if that 'progression' is noted on a single value, and also have implications for treatment in the clinical practice setting.
patients and methods
Patients with MTC (n = 39) enrolled on a RET kinase inhibitor studycabozantinib (XL184), tipifarnib with sorafenib, lenvatinib (E7080), or valproic acid with sorafenib or with sunitinib-in the Clinical Center of Targeted Therapy from July 2006 were assessed. Twenty-six patients were on study for at least 6 months, and they are the subject of this report. These studies and all treatments were conducted in accordance with MD Anderson Internal Review Board guidelines.
tumor response
Tumor response was evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) at baseline, at and about every 2 months thereafter [5] . RECIST measurements were carried out in the clinic by a tumor measurement team and confirmed by an attending physician and/or a radiologist.
tumor markers
Serum calcitonin and CEA levels were measured at baseline and at each restaging, using a double antibody radioimmunoassay (Diagnostic Systems Laboratories, Webster, TX) and the AxSYM microparticle enzyme immunoassay (Abbott Diagnostics, Abbott Park, IL), respectively. The coefficient of variation of the intraassay comparison for calcitonin was 5.3%, and that of the interassay comparison was 7.1% for 75 ng/l. The coefficient of intraassay variation for CEA was 2.4% at a mean value of 2.27 ng/ml (2.27 μg/l) and 2.4% at 20.74 ng/ml (20.74 μg/l); the interassay coefficient of variation was 3.1% at a mean value of 2.45 ng/ml (2.45 μg/l) and 2.8% at 18.75 ng/ml (18.75 μg/l). The upper limit of normal for calcitonin is 10 pg/ ml, and for CEA is 3.0 ng/ml for nonsmokers and 6.0 ng/ml for smokers.
RET mutation analysis
For RET mutation analysis, DNA was extracted using QIAamp DNA (or DNeasy) tissue kit (Qiagen, Hilden, Germany). Exons 10-20 of the gene encoding RET were sequenced to determine germline mutational status. In addition, in those individuals without a germline mutation, exons 0, 11, 13, 14, 15 and 16 were sequenced to determine somatic mutations.
statistical analysis
Most of the observations described herein are descriptive. Progression-free survival (PFS) was calculated using the Kaplan and Meier method [6] . Patients without progression at the date of last follow-up were censored at that date. results patients Twenty-six of 39 (67%) consecutive patients with MTC who were enrolled on trials with RET inhibitors remained on study for ≥6 months. Five of them were enrolled on two trials with RET inhibitors for ≥6 months for 31 enrollments. The median age was 53 years (range 33-89 years) and 19 of the patients (73%) were men. The median PFS was 16.0 months (95% CI 14.1-17.9). Patient demographics are described in Table 1 . Fourteen of the 26 patients (54%) achieved a partial response (PR) and the rest (46%) had stable disease (SD). Six patients were still receiving treatment as of 1 March 2012. The clinical features of each of the 26 patients are described in Table 2 .
tumor markers
All 26 patients showed elevated calcitonin levels at the start of their treatment, with the median baseline value being 5138 pg/ ml (range 11.9-555 603 pg/ml). A decline in calcitonin was observed in 100% of these patients, with a median decrease of 67% (range 3.3%-89%) with treatment. After the initial decline, the observed trend in 20 of the 26 patients (77%) was a fluctuation in calcitonin, which spiked above baseline in 9 patients (35%). In only 1 of these 9 patients ( patient 9) did the calcitonin never return to baseline; this patient has remained on study for over 16 months with a decline in tumor measurements of 40% (at 16 months). For the other 11 patients, the calcitonin reached a nadir plateau and then fluctuated up and down around that plateau (examples shown in Figure 1 , patients 25 and 26).
Twenty-two of 26 patients (85%) also presented with elevated CEA levels at the start of their treatment, with the median value being 182 ng/ml (range 17-2511 ng/ml) in those 22 patients. A decline in CEA was observed in 20 of the 22 patients (91%), with a median decrease of 56% (range 4.3-93%) in the 20 patients, with treatment. Fluctuations were observed in 11 of the 22 patients (50%) with elevated CEA, albeit less marked and not corresponding necessarily with the fluctuations of calcitonin (examples shown in Figure 2 , patients 3 and 24). CEA spiked above baseline in seven of the patients but, in all but three, returned to levels below baseline before the end of treatment. One of the three patients with continuously elevated CEA above baseline ( patient 9) was the patient described above whose calcitonin also remained elevated, but who had remained on study for 16 months with 40% tumor regression. The other two patients with persistently elevated CEA above baseline remained on study for about 15 and 13 months, respectively, at which time they had progressive disease by tumor measurements. Their best response was 3 and 37% decrease, respectively ( patients 21 and 10). majority of measurements were carried out by CT scan, with contrast as needed such as in the case of liver metastases). The fluctuations did not always correspond to changes in calcitonin and/or CEA. RECIST measurements remained below baseline in all but one of those patients and, in all patients, the progression above nadir was transient, and reversed with continued therapy at the same dose and schedule.
RET mutations
All 26 patients were tested for a germline RET mutation (hereditary MTC) and 9 (35%) were positive. Five were diagnosed with MEN2 syndrome. Seventeen (65%) patients did not have a germline RET mutation (sporadic MTC); 14 of these patients had tumor tissue available for testing and 7 (27%) were positive for somatic RET mutation (Table 2) .
discussion
It is well accepted that calcitonin and CEA are useful tools in the diagnosis and follow-up of MTC [7] . Although published reports of trials using kinase inhibitors indicate an immediate decline in tumor markers after the start of treatment, neither calcitonin nor CEA levels significantly correlated with the degree or duration of objective response [8, 9] . It has also been previously reported, in clinical trials with sorafenib [8] that, after an initial dramatic decline in calcitonin, a fluctuation (or bounce) can be observed; the bounce does not correlate with changes in objective response. Our report supports and expands on this observation. Indeed, we initially discerned an important decrease in tumor markers in the majority of patients, followed by fluctuations around the attained level. In most individuals, these fluctuations were much less pronounced than the original decline. These data suggest that short-term fluctuations in markers can be misleading; rather, long-term trends should be assessed.
RET inhibitors suppress calcitonin gene transcription and protein secretion in a manner that is independent of tumor growth inhibition [10] . It is still unclear to what degree posttreatment calcitonin changes are associated with transcription inhibition as opposed to tumor shrinkage, and whether fluctuations are the result of these two competing forces. No direct effect of RET inhibition on CEA expression has been noted [10] . ND, mutation analysis not done; SD, stable disease (<30% regression to <20% progression).
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Hypersecretion of calcitonin is present in virtually all patients with MTC, while CEA hypersecretion is not as definitive [11] . This heterogeneity could explain why fluctuations in calcitonin were not necessarily mimicked by changes in CEA ( patients 13 and 25 in Figure 1) . Historically, it has been expected that a change in tumor markers reflects a change in tumor size, but this was clearly not always the case. For example, in patients 22, 25 and 26 (Figure 1 ) calcitonin and CEA fluctuated, while RECIST measurements did not. The calcitonin of patient 22 increased above baseline value at times when RECIST measurements showed stable disease. The fluctuations in calcitonin and CEA are unlikely to be attributable to their clearance or lack thereof, because CEA and calcitonin half-life is about 5 days and 30 h, respectively [12, 13] ; tumor markers were measured every 6-8 weeks.
Of special interest, fluctuations in RECIST tumor measurements also occurred. For instance, in patients 16 and 17 ( Figure 3) , it was RECIST measurements that oscillated, even at times when tumor markers did not. Overall, 10 of 26 patients (36%) showed short-lived cycling of tumor measurements, including increases more than 20% above nadir values. Continued treatment at the same dose and schedule was associated with durable regression of tumor size in all of these patients (although in some cases, fluctuations continued to occur). Interestingly, RECIST measurements in patients 16 and 17 stabilized during treatment, even as both CEA and calcitonin rose. These observations cannot be easily explained. Overall, for the majority of our patients with MTC treated long term with RET inhibitors, calcitonin, CEA and RECIST oscillated throughout treatment, albeit not always at the same time.
There are several limitations to this study. First, this was a retrospective study; prospective validation of these observations is needed. Secondly, the patient population is relatively small. Thirdly, patients were enrolled on different clinical trials with different RET inhibitors, which does not allow us to make conclusions about any particular agent; however, the fact that these patients were receiving a variety of RET inhibitors suggests that the observed oscillating phenomenon is not a drug-specific issue. Finally, the impact of drug holidays was not assessed. Even a short drug holiday could conceivably have an effect if drug half-life is short. (Half-life for sorafenib is ∼1 day; cabozantinib has a longer half-life of ∼5-11 days [9] ).
In conclusion, our data indicate that RET inhibition therapy of MTC is characterized by frequent initial declines in tumor measurements and markers, and then a cycling pattern of response around a plateau. Atypical response patterns have previously been recognized with targeted agents in other tumors as well. For instance, in gastrointestinal stromal tumors (GIST) treated with KIT inhibitors, tumors may show increases in size by RECIST criteria while significant diminution in metabolic 
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activity is seen on PET scan and is accompanied by improvement in patient well-being; many of these patients show long-term response with ongoing treatment [14] . For this reason, alternative response criteria such as Choi have been proposed [15] . Newer agents, such as the immune modulator ipilimumab in melanoma, may also show distinct response patterns, including response after an initial increase in tumor burden or even after the development of new lesions [16] . For patients with MTC treated with RET inhibitors, basing treatment decisions on transient increases in tumor measurements or marker levels after a limited number of restaging exams may be misleading, as most patients described herein demonstrated renewed regression after continuing treatment at the same dose and schedule. It may not be surprising that tumor markers fluctuate in these patients, as short-term vacillations have previously been reported even in patients with MTC not treated with tyrosine kinase inhibitors [17] . Furthermore, fluctuations have been reported for other tumor markers, such as PSA for prostate cancer [18] . Our observations have important implications for the conduct of clinical trials as well as for general treatment decisions, and suggest that the classical practice of discontinuing therapy with progression of more than 20% above nadir as mandated by RECIST criteria and many protocols may need to be modified. Indeed, it appears that the removal of patients from study and/ or discontinuing drug based on short-term vacillations in markers or tumor size might be harmful to them, as a drug whose long-term effect is beneficial will have been discontinued based on a transient oscillation. Whether or not a similar cycling phenomenon occurs with the use of targeted agents in other cancers also warrants investigation. 
